The Vaccine Prep (ATA) therapy by RGCC is an immune therapy that enhances the immune system's ability to recognize and destroy cancer cells. By utilizing cellular fragments from dying circulating tumor cells (CTCs), this therapy stimulates the activation and development of dendritic cells, which play a critical role in initiating a targeted immune response. Here’s a detailed overview:

How Vaccine Prep (ATA) Works

1. Blood Sample Collection
   • A blood sample is taken from the patient to isolate CTC fragments, which include:
     • Cellular membranes
     • Intracellular organelles
     • Mitochondria
     • RNA and DNA
2. CTC Fragment Utilization
   • These fragments stimulate dendritic cells, training the immune system to recognize cancer-specific markers.
3. Immune System Activation
   • Once reinfused into the patient, the therapy activates dendritic cells to enhance the function of specific immune cells, enabling them to identify and attack cancer cells more effectively.
4. Long-Term Immunity
   • The therapy stimulates the development of immune memory cells, providing lasting protection against the cancer.

Administration Schedule

• Delivered as six single-dose injections (IV or subcutaneous), given weekly over nine weeks, including a three-week rest period after the first three doses.

Therapeutic Goals

• Eliminate existing cancer cells.
• Develop long-term immunity to prevent cancer recurrence.

Applications of Vaccine Prep (ATA)

1. For Solid Tumors
   • Effective for cancers where the tumor is not compartmentalized and the patient has not undergone conventional chemotherapy or radiation.
2. Early-Stage Cancers
   • Particularly beneficial for patients with early-stage cancers or stable disease who have not yet undergone immune-compromising treatments.

Key Benefits of Vaccine Prep (ATA)

1. Immune Activation:
   • Enhances the natural ability of the immune system to target and destroy cancer cells.
2. Long-Lasting Protection:
   • Provides immunity by training the body’s immune cells to recognize cancer markers.
3. Non-Toxic:
   • Does not use genotoxic drugs (e.g., chemotherapy) and has minimal side effects compared to conventional cancer treatments.
4. Non-Genetic Therapy:
   • Works by stimulating natural immune responses without altering genetic material.

Contraindications

Vaccine Prep (ATA) is not suitable for patients with:

• Active autoimmune diseases or
• High inflammation, cachexia, or other conditions compromising immune function.
• Recent or concurrent treatments like chemotherapy, radiation, or immunosuppressive therapies.
• Pregnancy or children under 18 years old.

Not Suitable For:

• Hematologic (blood) cancers
• CNS cancers
• Testicular cancer
• Compartmentalized cancers

The Vaccine Prep (ATA) therapy offers a powerful and non-toxic solution for patients with solid tumors. By harnessing the immune system's natural ability to recognize and destroy cancer cells, it provides immediate therapeutic benefits and long-term immunity, offering hope and protection for eligible patients.